{"id":1820,"date":"2023-10-20T13:46:18","date_gmt":"2023-10-20T13:46:18","guid":{"rendered":"https:\/\/www.lunit.io\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/"},"modified":"2025-11-01T05:47:52","modified_gmt":"2025-11-01T05:47:52","slug":"phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2","status":"publish","type":"publication","link":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/","title":{"rendered":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)"},"content":{"rendered":"

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)<\/h3>\n

Myung-Ju Ahn, Sehhon Park, Tae Min Kim, Ji-Youn Han, Gyeong-Won Lee, Byoung Yong Shim, Yun-Gyoo Lee, Sane-We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong-Hoon Shin, Chan-Young Ock, Byung-Ho Nam, Jeabong Lee, Hyun-Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn<\/p>\n

ESMO, 2023<\/strong><\/p>\n

Purpose<\/strong>
\nIn the treatment of non\u2013small-cell lung cancer (NSCLC) with a driver mutation, the role of anti\u2013PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-rearranged or translocated NSCLC upon progression on TKI therapy.<\/p>\n

Materials and Methods<\/strong>
\nWe compared the clinical efficacy of ABCP followed by maintenance therapy with atezolizumab plus bevacizumab with pemetrexed plus carboplatin or cisplatin (PC) followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS).<\/p>\n

Results<\/strong>
\nA total of 228 patients with activating EGFR mutation (n = 215) or ALK translocation (n = 13) were enrolled from 16 sites in the Republic of Korea and randomly assigned at 2:1 ratio to either ABCP (n = 154) or PC arm (n = 74). The median follow-up duration was 26.1 months (95% CI, 24.7 to 28.2). Objective response rates (69.5% v 41.9%, P < .001) and median PFS (8.48 v 5.62 months, hazard ratio [HR], 0.62 [95% CI, 0.45 to 0.86]; P = .004) were significantly better in the ABCP than PC arm. PFS benefit increased as PD-L1 expression increased, with an HR of 0.47, 0.41, and 0.24 for PD-L1 \u22651%, \u226510%, and \u226550%, respectively. Overall survival was similar between ABCP and PC arm (20.63 v 20.27 months, HR, 1.01 [95% CI, 0.69 to 1.46]; P = .975). The safety profile of the ABCP arm was comparable with that previously reported, with no additional safety signals, but higher rates of treatment-related adverse events were observed compared with the PC arm.<\/p>\n

Conclusion<\/strong>
\nTo our knowledge, this study is the first randomized phase III study to demonstrate the clinical benefit of anti\u2013PD-L1 antibody in combination with bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or translocated NSCLC who have progressed on relevant targeted therapy.<\/p>\n

View abstract<\/strong><\/a><\/p>\n","protected":false},"featured_media":0,"template":"","publication-oncology":[95,78,133,77,93],"publication-region":[],"publication-type":[],"radiology":[],"class_list":["post-1820","publication","type-publication","status-publish","hentry","publication-oncology-conference-posters","publication-oncology-lung-cancer","publication-oncology-lunit-scope-io","publication-oncology-tumor-type","publication-oncology-type-of-evidence"],"acf":[],"yoast_head":"\nPhase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) - Lunit<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) - Lunit\" \/>\n<meta property=\"og:description\" content=\"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) Myung-Ju Ahn, Sehhon Park, Tae Min Kim, Ji-Youn Han, Gyeong-Won Lee, Byoung Yong Shim, Yun-Gyoo Lee, Sane-We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Lunit\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-01T05:47:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@lunit_ai\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\\\/\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\\\/\",\"name\":\"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) - Lunit\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#website\"},\"datePublished\":\"2023-10-20T13:46:18+00:00\",\"dateModified\":\"2025-11-01T05:47:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/publication\\\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#website\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/\",\"name\":\"Lunit\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#organization\",\"name\":\"Lunit\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Logo-black.svg\",\"contentUrl\":\"https:\\\/\\\/www.lunit.io\\\/en\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Logo-black.svg\",\"width\":189,\"height\":52,\"caption\":\"Lunit\"},\"image\":{\"@id\":\"https:\\\/\\\/www.lunit.io\\\/ko\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/lunit_ai\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/lunit-inc\",\"https:\\\/\\\/x.com\\\/lunitoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) - Lunit","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/","og_locale":"en_US","og_type":"article","og_title":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) - Lunit","og_description":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) Myung-Ju Ahn, Sehhon Park, Tae Min Kim, Ji-Youn Han, Gyeong-Won Lee, Byoung Yong Shim, Yun-Gyoo Lee, Sane-We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki […]","og_url":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/","og_site_name":"Lunit","article_modified_time":"2025-11-01T05:47:52+00:00","twitter_card":"summary_large_image","twitter_site":"@lunit_ai","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/","url":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/","name":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04) - Lunit","isPartOf":{"@id":"https:\/\/www.lunit.io\/ko\/#website"},"datePublished":"2023-10-20T13:46:18+00:00","dateModified":"2025-11-01T05:47:52+00:00","breadcrumb":{"@id":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lunit.io\/en\/publication\/phase-iii-randomized-study-of-atezolizumab-plus-bevacizumab-and-chemotherapy-in-patients-with-egfr-or-alk-rearranged-or-translocated-non-small-cell-lung-cancer-attlas-kcsg-lu19-04-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lunit.io\/en\/"},{"@type":"ListItem","position":2,"name":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non\u2013Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)"}]},{"@type":"WebSite","@id":"https:\/\/www.lunit.io\/ko\/#website","url":"https:\/\/www.lunit.io\/ko\/","name":"Lunit","description":"","publisher":{"@id":"https:\/\/www.lunit.io\/ko\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lunit.io\/ko\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.lunit.io\/ko\/#organization","name":"Lunit","url":"https:\/\/www.lunit.io\/ko\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.lunit.io\/ko\/#\/schema\/logo\/image\/","url":"https:\/\/www.lunit.io\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","contentUrl":"https:\/\/www.lunit.io\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","width":189,"height":52,"caption":"Lunit"},"image":{"@id":"https:\/\/www.lunit.io\/ko\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/lunit_ai","https:\/\/www.linkedin.com\/company\/lunit-inc","https:\/\/x.com\/lunitoncology"]}]}},"_links":{"self":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication\/1820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/media?parent=1820"}],"wp:term":[{"taxonomy":"publication-oncology","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication-oncology?post=1820"},{"taxonomy":"publication-region","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication-region?post=1820"},{"taxonomy":"publication-type","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/publication-type?post=1820"},{"taxonomy":"radiology","embeddable":true,"href":"https:\/\/www.lunit.io\/en\/wp-json\/wp\/v2\/radiology?post=1820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}